

SCOPING REVIEW PROTOCOL:  
Heterogeneity and mixing in deterministic compartmental dynamical  
models of HIV transmission: a scoping review of parameterizations

Jesse Knight

February 20, 2020

## Contents

<b>1</b>	<b>General Information</b>	<b>2</b>
1.1	Identifying Information . . . . .	2
1.2	Background & Rationale . . . . .	2
1.3	Review Questions . . . . .	4
<b>2</b>	<b>Methods</b>	<b>4</b>
2.1	Eligibility Criteria . . . . .	4
2.2	Information Sources . . . . .	4
2.3	Search Strategy . . . . .	4
2.4	Data Management . . . . .	5
2.5	Selection Process . . . . .	5
2.6	Data Extraction . . . . .	6
2.7	Quality Assessment . . . . .	6
2.8	Data Synthesis [TBD] . . . . .	6
2.8.1	Question 1: Context . . . . .	6
2.8.2	Question 2: Parameterizations . . . . .	6
2.8.3	Question 3: Trends . . . . .	6
<b>A</b>	<b>Data Extraction Form</b>	<b>9</b>

# 1 General Information

## 1.1 Identifying Information

**Date:** 2020 February

**Principle Investigators & Affiliations:**

Jesse Knight<sup>1</sup>; Sharmistha Mishra<sup>1</sup>

<sup>1</sup>Institute of Medical Sciences, University of Toronto

**Co-Investigators:** TBD

**Review Title:**

*Heterogeneity and mixing in deterministic compartmental dynamical models of HIV transmission: a scoping review of parameterizations*

**Research Funding:** NSERC CGS-D

## 1.2 Background & Rationale

### Different Populations need Different HIV Interventions

Advances in HIV antiretroviral treatment (ART) have produced highly effective drug regimens, whereby circulating levels of HIV virus in adherent patients are reduced to undetectable levels [TBD]. Viral suppression by ART has clear individual-level benefits for health and quality of life [TBD]. Moreover, recent trials have suggested that virally suppressed individuals cannot transmit HIV, a finding described as: “undetectable = untransmittable” (U=U) [1]. Inspired by U=U, researchers and policymakers have called for rapid scale-up of ART coverage as the main intervention by which to reduce HIV incidence (“treatment as prevention”) in the widespread epidemics of Sub-Saharan Africa [TBD]. Global ambition to scale up ART coverage is further motivated by the UNAIDS 90-90-90 targets, defined as: 90% of people living with HIV are diagnosed; 90% of those diagnosed are on ART; and 90% of those on ART are virally suppressed.

Unfortunately, several large-scale trials aiming to demonstrate population-level impact of treatment as prevention in Sub-Saharan Africa have failed to show a significant reduction in new infections [2, 3, 4]. As suggested by Baral et al. [5] and others, these unexpected results might be attributable to implementation challenges at scale. Such challenges can emerge at several steps along the treatment cascade, including: testing for HIV, linkage to care after a positive test, starting ART after linkage to care, achieving viral suppression after starting ART [TBD]. Moreover, individuals who are most likely to experience challenges in HIV care are often at the highest risk of HIV acquisition and onward transmission [TBD]. Groups of vulnerable individuals in the epidemic are sometimes described as “key populations”.

Several key populations have been identified, including: adolescent girls and young women; sex workers; men who have sex with men; transgender people; prisoners; and people who inject drugs [6]. Key populations often experience several risk factors for HIV transmission and barriers to care, such as: violence and coercion into unsafe sex; criminalization of lifestyle; stigma related to lifestyle or HIV status; housing and financial instability; and substance abuse [7, 6]. To meet the unique HIV prevention and treatment needs of key populations, specific interventions are needed which address known vulnerabilities [6]. For example, risk of HIV transmission can be reduced through needle exchange programs [8], increased access to condoms [TBD], and financial support to reduce transactional sex [9]. Similarly, outreach and support by community peers can increase engagement of key populations in HIV care [6].

Despite considerable evidence supporting the need for diversified HIV interventions, recent large-scale studies of treatment as prevention have not considered the unique needs of key populations [2, 3, 4]. Failure to

deliver appropriate interventions to key populations has left these groups far behind global progress toward the 90-90-90 targets [10], threatening to undermine the expected benefits of treatment as prevention.

## Mathematical Modelling of HIV Transmission

Population-level models of HIV transmission have long been used to project HIV epidemic trajectories (e.g. incidence over time) and predict intervention impacts (e.g. reduction in incidence after X years) [11]. In popular compartmental models, overall populations are stratified by disease state and risk group, while differential equations are used to govern movement of individuals between compartments. Many different compartmental model structures have been used, from a 3-compartment model, representing 3 disease states in a homogeneous population [12], to a 294-compartment model, representing 21 disease states and 14 risk groups [13].

Unfortunately, differences in model structure and assumptions have been shown to substantially influence projections of epidemic trajectory and intervention impact [11, 14]. Most importantly, failure to model heterogeneity in risk results in lower basic reproduction number  $R_0$  [15], which could lead to overestimated ease of epidemic control through universal treatment as prevention [14]. And yet, several mathematical models that were used to support treatment as prevention did not consider heterogeneity in risk of HIV acquisition or transmission [TBD, 16, 11]. Even models that did consider risk heterogeneity rarely acknowledged known differences in the treatment cascade across risk groups [TBD, 11], such as among key populations [10]. Knight et al. [17] showed that the modelled impact of achieving 90-90-90 in a population overall was highly dependent on which risk groups were left behind in the remaining “10-10-10”, emphasizing that differences in treatment cascade cannot be ignored. Finally, simulated sexual mixing between risk groups has generally been simpler than observed in reality [TBD], with potential implications for validity of modelling results. For example, Wang et al. [18] have shown that failure to model assortative mixing by HIV status among men who have sex with men may result in underestimated impact of pre-exposure prophylaxis.

One major reason why risk groups and mixing may be missing from HIV transmission models is lack of data. Despite best efforts, key populations are often not captured by large-scale demographic and health surveys, such as those by USAID [19], due to several barriers: household-based sampling methodologies, criminalization of lifestyle, social desirability bias, and stigma [20]. For example, in the 2006-07 Eswatini demographic and health survey [21] just 0.2% male respondents reported paying for sex, while estimates of commercial sex client populations in similar regions were as high as 8% [22]. In many cases, parallel surveys with specific sampling methodologies and community involvement can overcome these barriers, facilitating data collection on key populations [23]. Moreover, collection of key populations data can and should be integrated with modelling work and evaluation of tailored interventions.

## Future Work

This review aims to identify parameterizations of risk heterogeneity and mixing used in previous transmission models of HIV in Sub-Saharan Africa. Identified parameterizations will then be considered in a systematic model comparison study, similar to that by Hontelez et al. [14]. For example, the projected impact of universal treatment as prevention will be compared in models with versus without female sex workers, or in models with versus without mixing by risk group. In comparing parameterizations, potential biases and uncertainties associated with simpler models can be estimated. Furthermore, considering the importance of data to inform complex models, the model comparison study will identify key pieces of information which are necessary to construct accurate models, so that these data may be prioritized for collection going forward.

### 1.3 Review Questions

1. In which contexts (geographies, populations, time periods) within Sub-Saharan Africa, and for what purposes (research questions) have HIV transmission models been used?
2. What parameterizations have been used to represent risk heterogeneity and mixing in compartmental HIV transmission models?
3. How are parameterizations of risk heterogeneity and mixing (2) in HIV transmission models associated with specific contexts and applications (1)?

## 2 Methods

### 2.1 Eligibility Criteria

#### Publication Details:

##### *Include*

- English language
- published before 2020
- non-review peer-reviewed journal article

##### *Exclude*

- non-English language
- published in 2020 or later
- non-peer reviewed journal article
- review article (references will be screened)
- textbook, grey literature, opinions, comments, conference abstracts

#### Mathematical Model of Transmission:

##### *Include*

- deterministic model
- compartmental model
- dynamical model
- between-host dynamics

##### *Exclude*

- stochastic (random) model
- individual-based model
- non-dynamical model
- within-host / sub-cellular dynamics only
- no mathematical modelling

#### HIV Infection:

##### *Include*

- HIV infection modelled

##### *Exclude*

- other infections modelled

### 2.2 Information Sources

#### Databases:

- MEDLINE
- EMBASE

### 2.3 Search Strategy

#### Search Terms:

##### *Publication Details*

TBD

### *Mathematical Model of Transmission*

("Computer Simulation/" OR "Models, Biological/" OR "Mathematical Computing/") AND ("Disease Transmission, Infectious/")

### *HIV*

("HIV Infections/" OR "HIV/")

### **Validation References:**

- [24] (1994) Garnett and Anderson *"Balancing sexual partnership in an age and activity stratified model of HIV transmission in heterosexual populations"*
- [16] (2009) Granich et al. *"Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model"*
- [25] (2014) Eaton and Hallett *"Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidence"*
- [26] (2015) Henry and Koopman *"Strong influence of behavioral dynamics on the ability of testing and treating HIV to stop transmission"*
- [27] (2017) Maheu-Giroux et al. *"Population-level impact of an accelerated HIV response plan to reach the UNAIDS 90-90-90 target in Côte d'Ivoire: Insights from mathematical modeling"*
- [28] (2018) Mukandavire et al. *"Estimating the contribution of key populations towards the spread of HIV in Dakar, Senegal"*

**Results:** February 20, 2020

MEDLINE: total (validation)

- 47 (0): ("Computer Simulation/" OR "Models, Biological/" OR "Mathematical Computing/") AND ("Disease Transmission, Infectious/") AND ("HIV Infections/" OR "HIV/")
- 2523 (2): ("Computer Simulation/" OR "Models, Biological/" OR "Mathematical Computing/") AND ("HIV Infections/" OR "HIV/")

## **2.4 Data Management**

After performing an initial search in the named databases, the bibliographic information (including abstract) of non-duplicate matching items will be exported from the search result in XML format, and uploaded to Covidence for abstract screening. Covidence provides tools for including and excluding items by multiple reviewers based on a set of user-defined criteria, tracking the results of review and highlighting conflicts.

The full texts of included items will then be sought using institutional access and support. For each item, the data extraction form given in Appendix A (Google Forms) will be completed. Upon submission of the form, a row in the linked tabular database (Google Sheets) will be automatically populated with the results. Analysis of the tabular data will then be performed in Python, with the aim of generating statistics and figures to answer the [Review Questions](#).

## **2.5 Selection Process**

Following upload of the initial search results to Covidence, two reviewers (JK, TBD) will screen the abstracts for inclusion using the [Eligibility Criteria](#). Decision conflicts will be resolved by discussion, mediated by a third reviewer (SM) where necessary.

## 2.6 Data Extraction

Appendix A gives the data extraction form to be used for each included reference. The form includes a combination of short text inputs and pre-defined categorical variables in the following sections:

- Article meta-data: authors, journal, title, etc.
- Model context: geography, time, research questions
- Model approach: model type, code
- Modelled populations: sex, age, risk, turnover, interventions
- Modelled biology: CD<sub>4</sub>, viral load, treatment
- Modelled transmission: modes, types of acts, partnership types, modifiers
- Data: calibration targets

Some short text inputs will capture semi-structured data, such as the relative sizes of population strata, like:

HSF-low: 0.35, HSF-medium: 0.125, HSF-high: 0.025, ...

corresponding to: heterosexual females in the low risk group representing .35 proportion of the total population, etc. Provided the input are structured in the suggested way, the text can later be parsed in Python, even though the population strata definitions may change from model to model.

Data extraction will be completed by one reviewer (JK).

## 2.7 Quality Assessment

N/A

## 2.8 Data Synthesis [TBD]

### 2.8.1 Question 1: Context

### 2.8.2 Question 2: Parameterizations

### 2.8.3 Question 3: Trends

## References

- [1] Robert W. Eisinger, Carl W. Dieffenbach, and Anthony S. Fauci. *HIV viral load and transmissibility of HIV infection undetectable equals untransmittable*. 2019.
- [2] Collins C. Iwuji et al. "Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial". In: *The Lancet HIV* 5.3 (2018), e116–e125. URL: <http://www.ncbi.nlm.nih.gov/pubmed/29199100>.
- [3] D Havlir et al. "SEARCH community cluster randomized study of HIV "test and treat" using multi- disease approach and streamlined care in rural Uganda and Kenya". In: *International AIDS Conference 2018*. Amsterdam, Netherlands, 2018. URL: <https://programme.aids2018.org/Abstract/Abstract/13469>.
- [4] Richard J. Hayes et al. "Effect of universal testing and treatment on HIV incidence - HPTN 071 (popart)". In: *New England Journal of Medicine* 381.3 (2019), pp. 207–218.
- [5] Stefan Baral et al. "The disconnect between individual-level and population-level HIV prevention benefits of antiretroviral treatment". In: *The Lancet HIV* (2019). URL: [http://doi.org/10.1016/s2352-3018\(19\)30226-7](http://doi.org/10.1016/s2352-3018(19)30226-7).
- [6] WHO. *Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations*. Tech. rep. 2014. URL: [https://apps.who.int/iris/bitstream/handle/10665/128048/9789241507431{\\\_}.eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/128048/9789241507431{\_}.eng.pdf).
- [7] Elisa Mountain et al. "Antiretroviral therapy uptake, attrition, adherence and outcomes among hiv-infected female sex workers: A systematic review and meta-analysis". In: *PLoS ONE* 9.9 (2014), e105645. URL: <https://dx.plos.org/10.1371/journal.pone.0105645>.
- [8] Ann E. Kurth et al. *Combination HIV prevention: Significance, challenges, and opportunities*. 2011.
- [9] Audrey Pettifor et al. *Can money prevent the spread of HIV? A review of cash payments for HIV prevention*. 2012.
- [10] Somya Gupta and Reuben Granich. *National HIV Care Continua for Key Populations*. 2017. URL: <http://journals.sagepub.com/doi/10.1177/2325957416686195>.
- [11] Jeffrey W. Eaton et al. "HIV treatment as prevention: Systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa". In: *PLoS Medicine* 9.7 (2012), e1001245. URL: <https://dx.plos.org/10.1371/journal.pmed.1001245>.
- [12] Seyed M. Moghadas et al. "Could condoms stop the AIDS epidemic?" In: *Journal of Theoretical Medicine* 5.3-4 (2003), pp. 171–181.
- [13] Cliff C. Kerr et al. "Optima: A Model for HIV Epidemic Analysis, Program Prioritization, and Resource Optimization". In: *Journal of Acquired Immune Deficiency Syndromes* 69.3 (2015), pp. 365–376. URL: <http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage{\&}an=00126334-201507010-00017>.
- [14] Jan A.C. C. Hontelez et al. "Elimination of HIV in South Africa through Expanded Access to Antiretroviral Therapy: A Model Comparison Study". In: *PLoS Medicine* 10.10 (2013), e1001534. URL: <http://dx.plos.org/10.1371/journal.pmed.1001534>.
- [15] R. M. Anderson et al. "A preliminary study of the transmission dynamics of the Human Immunodeficiency Virus (HIV), the causative agent of AIDS". In: *Mathematical Medicine and Biology* 3.4 (1986), pp. 229–263. URL: <https://academic.oup.com/imammb/article-lookup/doi/10.1093/imammb/3.4.229>.
- [16] Reuben M Granich et al. "Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model". In: *The Lancet* 373.9657 (2009), pp. 48–57. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19038438http://linkinghub.elsevier.com/retrieve/pii/S0140673608616979>.
- [17] Jesse Knight et al. "Who is left in 10-10-10? Importance of reaching key populations with the HIV cascade [Poster]". In: *Conference on Retroviruses and Opportunistic Infections - CROI*. Seattle, WA, USA, 2019. URL: <http://www.croiconference.org/sessions/who-left-10-10-10-importance-reaching-key-populations-hiv-cascade>.
- [18] Linwei Wang et al. "Influence of serosorting on the population-level transmission impact of pre-exposure prophylaxis among men who have sex with men: a mathematical modeling study". In: *TBD* (in preparation).
- [19] USAID. *The DHS Program*. 1984. URL: <https://www.dhsprogram.com>.
- [20] Abu S Abdul-Quader, Andrew L Baughman, and Wolfgang Hladik. *Estimating the size of key populations: Current status and future possibilities*. 2014. URL: <http://doi.org/10.1097/COH.0000000000000041>.
- [21] Macro International Inc. and Swaziland Central Statistical Office. *Swaziland: Demographic and Health Survey 2006-2007*. 2008. URL: <http://catalog.ihns.org/index.php/catalog/2463>.
- [22] M. Carael et al. "Clients of sex workers in different regions of the world: Hard to count". In: *Sexually Transmitted Infections* 82.SUPPL. III (2006), pp. iii26–iii33.
- [23] TBD and USAID. *Characterizing the HIV Prevention and Treatment Needs among Key Populations, including Men who Have Sex with Men and Female Sex Workers in Swaziland: From Evidence to Action*. Tech. rep. 2015.
- [24] Geoffrey P. Garnett and Roy M. Anderson. "Balancing sexual partnership in an age and activity stratified model of HIV transmission in heterosexual populations". In: *Mathematical Medicine and Biology* 11.3 (1994), pp. 161–192. URL: <https://academic.oup.com/imammb/article-lookup/doi/10.1093/imammb/11.3.161>.
- [25] Jeffrey W. Eaton and Timothy B. Hallett. "Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidence". In: *Proceedings of the National Academy of Sciences* 111.45 (2014), pp. 16202–16207. URL: <http://www.pnas.org/content/111/45/16202http://www.pnas.org/lookup/doi/10.1073/pnas.1323007111>.

- [26] Christopher J. Henry and James S. Koopman. "Strong influence of behavioral dynamics on the ability of testing and treating HIV to stop transmission". In: *Scientific Reports* 5.1 (2015), p. 9467. URL: <http://www.ncbi.nlm.nih.gov/pubmed/25902018><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5386110><http://www.nature.com/articles/srep09467>.
- [27] Mathieu Maheu-Giroux et al. "Population-level impact of an accelerated HIV response plan to reach the UNAIDS 90-90-90 target in Côte d'Ivoire: Insights from mathematical modeling". In: *PLoS Medicine* 14.6 (2017), e1002321. URL: <http://dx.plos.org/10.1371/journal.pmed.1002321>.
- [28] Christinah Mukandavire et al. "Estimating the contribution of key populations towards the spread of HIV in Dakar, Senegal". In: *Journal of the International AIDS Society* 21 (2018), e25126. URL: <http://www.ncbi.nlm.nih.gov/pubmed/30033604><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6055131><http://doi.wiley.com/10.1002/jia2.25126>.



## A Data Extraction Form

# Data Extraction Form

Heterogeneity in compartmental models of HIV transmission: a systematic review of parameterizations

### Article Meta-Data

1. Year

Year of publication

---

2. Authors

e.g. First Last, First Last, ...

---

3. Journal

---

4. URL

---

5. Bib ID

For cross-linking with reference management software

---

### Context

6. Geography Scale

What geography is modelled?

*Tick all that apply.*

- ☐ Illustrative
- ☐ Regional
- ☐ National
- ☐ Province
- ☐ City

7. Geography Name

Name of the modelled geography

---

8. t0

What year was the simulation started? For illustrative models, use "0"

---

9. t1

What year was the simulation stopped? For illustrative models, use the duration of the simulation

---

10. Key Populations

KP included in the model

*Tick all that apply.*

- ☐ FSW
- ☐ Clients
- ☐ AGYW
- ☐ GBMSM
- ☐ Trans
- ☐ PWID
- ☐ Infants

11. Research Questions

*Tick all that apply.*

- ☐ Project HIV Prevalence / Incidence
- ☐ Intervention Impact
- ☐ tPAF of Risk Groups
- ☐ Cohort / Trial Simulation

Other: ☐ \_\_\_\_\_

Model: Approach

12. Model Type

*Mark only one oval.*

- ☐ Compartmental
- ☐ Individual

13. Model Stochasticity

*Mark only one oval.*

- ☐ Deterministic
- ☐ Stochastic

14. Language

*Tick all that apply.*

- ☐ R
- ☐ Python
- ☐ C
- ☐ Excel
- ☐ Java
- ☐ Matlab

15. Code

Open source URL, if available

\_\_\_\_\_

## Model: Populations

### 16. Sex & Orientation

e.g. HSM, HSF, MSM, ... or NA if sex / orientation was not modelled

---

### 17. Age Groups

e.g. 15-20, 21-35, 35-55 or NA if age was not modelled

---

### 18. Risk Strata by

*Tick all that apply.*

☐ Number of Partners

Other: ☐ 

---

### 19. Risk Strata Defined

e.g. female-low: 1 partner, female-medium: 5 partners, female-high: 25 partners, ...

---

### 20. Risk Strata Sizes

e.g. female-low: 0.35, female-medium: 0.125, female-high: 0.025, ...

---

### 21. Turnover

Individuals move between which strata

*Tick all that apply.*

☐ Age

☐ Risk

## 22. Interventions & Strata

*Tick all that apply.*

	Universal	by year	by CD4	FSW	Clients	AGYW	GBMSM	Trans	PWID	Infants
ART	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
PrEP	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
PEP	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
HIV Vaccine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
PMTCT	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
STI Treatment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
TB Treatment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
VMMC	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Condoms	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Behaviour Change	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Needle Exchange	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Model: Biology

## 23. CD4 Strata

e.g. <100, 100-200, 200-350, >350 or NA if CD4 was not modelled

---

## 24. VL Strata

e.g. <10<sup>6</sup>, <10<sup>5</sup>, <10<sup>4</sup>, <10<sup>3</sup>, <10<sup>2</sup>, <10<sup>1</sup> or NA if VL was not modelled

---

25. Treatment Strata

e.g. PrEP, PEP, uDx, Dx, ART, ART-fail or NA if Treatment was not stratified

---

Model: Transmission

26. Transmission Resolution

*Mark only one oval.*

☐ Act

☐ Partnership

27. Transmission Modes

*Tick all that apply.*

☐ Heterosexual Sex

☐ Anal Sex

☐ Needle Sharing

☐ Mother to Child

28. Types of Partnerships

*Tick all that apply.*

☐ Generic

☐ Main

☐ Casual

☐ Commercial

☐ Transactional

☐ Needle Sharing

29. Associative Mixing by

*Tick all that apply.*

☐ Age

☐ Risk

☐ Serostatus

### 30. Transmission Modifiers

*Tick all that apply.*

- ☐ Condoms
- ☐ Male Circumcision
- ☐ STI Coinfection
- ☐ PrEP
- ☐ PEP
- ☐ Positioning

### Data

### 31. Prevalence Targets

*Tick all that apply.*

- ☐ Overall
- ☐ by Sex
- ☐ by Age
- ☐ by Risk
- ☐ KP specific

### 32. Incidence Targets

*Tick all that apply.*

- ☐ Overall
- ☐ Sex
- ☐ Age
- ☐ Risk
- ☐ Key Populations

---

This content is neither created nor endorsed by Google.

Google Forms